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Chronic venous disease, a disorder involving venous
return from the legs, is a growing epidemic in the
developed world. Numerous studies have been con-
ducted in the past two decades in an attempt to
elucidate its underlying pathophysiology. Many the-
ories have been proposed to address the profound
inflammatory dysregulation, with the majority focusing
on fibrin trap, inflammatory trap, cytokines, growth
factors, and matrix metalloproteinases. Although many
of these theories have obtained great momentum,
much of the data are contradictory. Moreover, many
treatments built on these theories have claimed over-
whelming success despite insufficient evidence. At the
same time, there are few reviews that critically analyze
and evaluate these data. Therefore, in this paper, we
will provide summaries of the background data and
evolution of these theories and examine their support-
ing evidence.
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INTRODUCTION
Chronic venous disease is common in Europe and the United
States, with more than 25 million adults in the United States
affected by the disease (Beebe-Dimmer et al., 2005). About
half of the venous ulcers heal after 10 weeks with
compression treatment, costing roughly $2,000 per patient
(Marston et al., 1999). Together, the social and economic
impact of chronic venous disease poses a great burden on
both patients and the general health care system.
The term chronic venous disease refers to a full spectrum
of venous changes, ranging from varicose veins and hyper-
pigmentation to lipodermatosclerosis and venous ulcers.
Therefore, given such a wide range of disease manifestations,
a classification system has been implemented. Using clinical,
etiological, anatomical, and pathophysiological classifica-
tions venous ulcers can be grouped from C0 to C6, with C0
having no sign of venous disease to C6 where active venous
ulcer is present.
Currently, the mechanism of injury and inflammation
behind chronic venous ulcer remains unknown. Various
theories have been devised to explain the pathophysiology
behind the inflammatory and repair processes. In a 2007
review paper, Eming et al. (2007) discussed the various
possible contributing factors to the chronic, non-healing,
inflammatory states of chronic venous disease, such as
unregulated matrix metalloproteinase (MMP) and imbalanced
cytokines.
Thus, this article will discuss the evolution of these
theories and critically review the currently findings and
available treatments.
RESULTS
‘‘Fibrin cuff’’ theory
The initial hypothesis concerning the pathophysiology
behind venous ulceration came in 1982 from Burnand
et al. (1982a, b) when they first described faster fibrinogen-
fibrin deposition around the capillary bed in canine hind limb
with elevated venous pressure. They postulated that the
elevated intravascular pressure causes enlargement of the
endothelial pores, leading to increased fibrinogen deposition
into the interstitium. Their further study demonstrated the
existence of a ‘‘fibrin cuff’’ that surrounds the dermal
capillaries in patients with lipdermatosclerosis and that a
1-mm thick fibrin membrane can decrease oxygen perme-
ability by B20-fold (Burnand et al., 1982a, b). Therefore,
they argued that the fibrin cuff creates an exchange barrier
that inhibits adequate diffusion of oxygen and nutrients,
leading to a state of tissue deficit that impairs proper wound
healing. However, in 1990, Cheatle et al. (1990) questioned
this idea of an impermeable barrier in their study that failed to
demonstrate decreased permeability of 133 Xenon, a
molecule with diffusion characteristics similar to those of
oxygen. They argued that the fibrin cuff that is deposited
around the capillary bed was probably of different composi-
tion than the 1-mm fibrin used, as it was manufactured by a
commercial surgical suture manufacturer for tissue repair
procedures. Later studies supported this notion, showing that
fibrin cuffs can be found in other chronic ulcerative diseases,
and that the venous oxygen tension in these diseases was
much higher compared with that observed for chronic venous
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insufficiency, suggesting that the significantly decreased
venous oxygen tension is a feature specific to chronic venous
disease rather than one associated with all fibrin cuffs
(Neumann et al., 1996; Joshi and Sloan, 2004). Evaluation
of the composition and progression of fibrin cuff also
revealed that the fibrin cuff is a highly organized structure
composed of laminin, fibronectin, tenascin, collagen, fibrin,
and trapped leukocytes, suggesting fibrosis activity rather
than mere fibrin deposition (Herrick et al., 1992).
Inflammatory ‘‘trap’’ theory
The trap theory developed as an extension of the fibrin cuff
theory, suggesting that various growth factors and inflamma-
tory cells may become trapped in the fibrin cuff. The
abnormal deposition of these inflammatory cells promotes
uncontrolled inflammation in the surrounding tissue, whereas
the sequestration of growth factors and cytokines prevents
proper wound regeneration (Falanga and Eaglstein, 1993).
Early studies in rat models suggested that rat leukocytes
become trapped in the capillaries in response to reduced
vascular flow rate, leading to capillary occlusion (Braide
et al., 1984). Thomas et al. (1988) later showed that patients
with venous hypertension, on average, exhibited 24% fewer
leukocytes returning from feet that had been dependent for
60minutes. In 1988, Coleridge Smith et al. (1988) postulated
that in patients with chronic venous disease, leukocytes
become trapped in capillaries, leading to the release of
proteolytic enzymes and reactive oxygen metabolites that
causes endothelial damage. The injured capillaries become
more permeable to macromolecules, exacerbating the fibrin
deposition. In addition, occlusion created by the leukocytes
causes local ischemia, which leads to further tissue hypoxia
and reperfusion damage.
Initially, no evidence of systemic activation of neutrophil
(Pappas et al., 1995) or microvascular occlusion (Wilkinson
et al., 1993) was detected. However, a later study with
wound fluid analysis supported the hypothesis, showing
increased levels of inflammation and hypoxia in the
microenvironment of the venous ulcer (Trengove et al.,
1996). Two studies also showed increased levels of inter-
cellular adhesion molecule-1 and vascular cell adhesion
molecule-1 in chronic venous insufficiency patients, suggest-
ing increased potential for leukocyte–endothelial adhesion
(Weyl et al., 1996; Saharay et al., 1998). Saharay et al. (1997)
later found that, after 30minutes of venous hypertension,
patients with chronic venous disease exhibited decreased
levels of neutrophil CD11b and L-selectin and increased
plasma levels of soluble L-selectin. This suggests that
leukocytes shed L-selectin upon attachment to the endothe-
lium. Takase et al. (1999) also revealed that fewer numbers of
activated neutrophils were found in patients’ whole blood
than in healthy blood incubated in patient plasma, suggesting
possible trapping of activated neutrophils in peripheral
circulation in chronic venous disease patients.
Besides neutrophils, other studies suggest the possible
involvement of T lymphocytes, B lymphocytes, macrophages
(Wilkinson et al., 1993; Loots et al., 1998), monocytes,
platelets (Peyton et al., 1998), and mast cells (Pappas et al.,
1997; Abd-El-Aleem et al., 2005) in the pathogenesis of
inflammation. Specifically, Loots et al. (1998) found an
increased presence of macrophages, B cells, and plasma cells
in chronic wounds compared with an acute wound healing
model. Similarly, Wilkinson et al. (1993) looked at 28 skin
biopsies from 23 patients with varicose veins in their lower
limbs and found a high level of infiltration of T lymphocytes
and macrophages.
Building on the theory of possible underlying inflamma-
tion and cellular dysfunction, the use of anti-inflammatory
medications is hypothesized as a solution to the underlying
inflammatory processes. Of all the anti-inflammatory medi-
cations used to treat venous leg ulcers, flavonoid, a
pigmented, polyphenolic compound naturally synthesized
by plants, is the most extensively studied. It is postulated to
act by protecting cells from damage caused by hypoxia,
decreasing permeability and fragility of vein vales and venous
walls, free radical formation, and affect expression of
adhesion molecules in granulocytes such as neutrophils
(Danielsson et al., 2003; Pascarella et al., 2005). Others
have also found it to increase venous elasticity (Ibegbuna
et al., 1997) and lymph drainage (Allegra et al., 1998).
Among the various flavonoids available, Daflon 500, a
micronized purified flavonoid fraction comprised of two
flavinoids, 450mg of micronized diosmin and 50mg of
hesperidin, is the most extensively studied formulation. An
industry-sponsored meta-analysis of Daflon 500 showed
increased healing in patients who received adjunctive Daflon
500 compared to those treated with conventional therapy
alone (Coleridge Smith, 2005). Currently, a Cochrane review
is being done on the efficacy of flavonoids for treating venous
leg ulcers (Scallon and Bell-Sayer, 2007). Other agents that
are explored include oral aspirin (Layton et al., 1994) and
pale sulfonated shale oils (Beckert et al., 2006).
Cytokines/growth factors
In addition to trapping of inflammatory cells, the ‘‘trap’’
theory has been broadened to include the trapping of various
cytokines and growth factors, leading to improper regulation
in wound healing. At the same time, others have speculated
that possible dysregulation of pro-inflammatory cytokines
and growth factors may be the key to the chronicity of the
disease.
One study showed that overall cytokine and growth factor
levels in keratinocytes of chronic leg ulcers were greater in
non-healing ulcers than in healing ulcers (Tian and Stacey,
2003). Another demonstrated that successful treatment led to
decreases in these pro-inflammatory factors (Beidler et al.,
2009). Two other studies, on the other hand, showed no
significant overall difference in either cytokine or growth
factor concentration between healing and non-healing
venous ulcer wounds (Harris et al., 1995; Trengove et al.,
2000; Gohel et al., 2008).
Tumor necrosis factor-a (TNF-a). TNF-a is a proinflamma-
tory cytokine widely involved in various systemic illnesses,
such as rheumatoid arthritis, Crohn’s disease, and psoriasis.
Its extensive involvement in systemic inflammation and our
www.jidonline.org 819
YC Liu et al.
Inflammation in Venous Ulcers: Critical Review
current availability of treatment make TNF-a an ideal target
cytokine for the study of chronic venous disease. An early
study with immunostaining detected TNF-a at the venous
ulcer bed along with undegraded fibrin (Claudy et al., 1991).
Subsequently, six studies (Mendez et al., 1999; Murphy et al.,
2002; Cowin et al., 2006; Wallace et al., 2006; Jull et al.,
2007; Charles et al., 2009) showed a correlation between
TNF-a and the non-healing state of venous ulcers. Two
studies revealed higher levels of TNF-a in non-healing ulcers
compared with healing ulcers (Murphy et al., 2002; Charles
et al., 2009). Another study showed that carriage of the
TNFA-308A allele was associated with increased risk of
venous leg ulcer development, with an adjusted odds ratio of
2.48 (95% confidence interval 1.54–3.97; P¼ 0.000155;
Wallace et al., 2006).
Mendez et al. (1999) applied wound fluid from chronic
venous ulcers to fibroblasts and showed decreased fibroblast
proliferation and increased senescence. Additional fibroblasts
were treated with TNF-a, which also demonstrated an
increased level of senescence compared with the control.
These data suggested that an unknown molecule in the
venous ulcer microenvironment, possibly TNF-a, induced
fibroblast senescence, leading to formation of chronically
non-healing ulcers. Since then, two studies have shown that
fibroblasts cultured in chronic venous ulcer fluid exhibit
increased proliferation when treated with inhibitors of either
TNF-a (Cowin et al., 2006) or p38, a downstream protein in
the TNF-a signaling pathway (Raffetto et al., 2008). A meta-
analysis done in 2007 by the Cochrane Collaboration looked
at 12 randomized controlled studies on pentoxifylline, an
inhibitor of prostaglandin E known to have anti-TNFa
properties, and concluded that it was effective alone
and with compression in treating venous ulcers (Jull et al.,
2007).
On the other hand, Wallace and Stacey (1998) found that
although the immunoreactive levels of TNF-awere much higher
in non-healing chronic ulcers, the levels of bioactive TNF-a
between healing and non-healing ulcers were relatively the
same. These data suggested that the initiation of healing was not
followed by a significant change in the level of bioactive TNF-a,
and that the level of TNF-a may not be the main regulator of
healing in chronic venous ulcers.
Ambrosch et al. (2008) showed that venous ulcers with
mixed bacterial infection had increased TNF-a levels compared
with monomicrobial infection, suggesting that elevation of
TNF-a may also correlate with severity of infection.
Transforming growth factor-b (TGF-b). TGF-b is among the
most commonly studied cytokines in relation to chronic venous
ulcer disease, given its functional role in cellular proliferation
and tissue regeneration. Using immunohistochemical staining,
Higley et al. (1995) detected high concentrations of TGF-b
in the fibrin cuff of chronic venous ulcers compared with
its distribution in the granulation tissue and adjacent dermal
matrix. TGF-b is one of the cytokines whose sequestration in the
fibrin cuff is thought to have a significant role in the chronicity
of ulceration. Both in vitro and in vivo studies have shown that
venous ulcer-derived fibroblasts are unresponsive to TGF-b
(Hasan et al., 1997; Cowin et al., 2001), possibly attributable to
decreased levels of TGF-b and TGF-b type II receptor in non-
healing chronic venous ulcers (Cowin et al., 2001; Kim et al.,
2003). This decrease is accompanied by failure of TGF-b signal
transduction in ulcer fibroblasts due to a lack of Smad2, Smad3,
and p42/44 mitogen-activating protein kinase phosphorylation
(Kim et al., 2003). Further investigation by Lal et al. (2003)
showed that although fibroblasts from class 5 and 6 venous
diseases did not respond to TGF-b1 stimulation, the diminished
proliferative response was reversible in fibroblasts from class
4 venous disease. The latest study by Pappas et al. (2009)
suggested that induction of fibroblasts into a contractile
phenotype by TGF-b may involve regulation of extracellular-
signal-regulated kinases 1 and 2 and MAPK. Overall, the level
of TGF-b1 was found to positively correlate with ulcer healing
(Gohel et al., 2008).
Others. Aside from TNF-a and TGF-b, other cytokines and
growth factors have been examined.
One randomized, double-blinded, placebo controlled study
(n¼60) showed that treatment with granulocyte-macrophage
colony-stimulating factor achieved a higher rate of complete
wound closure than placebo (Da Costa et al., 1999).
Another randomized, double-blinded, placebo controlled
study (n¼94) focused on keratinocyte growth factor 2, and
found that its application allowed more wounds to achieve
75% closure than placebo (Robson et al., 2001).
Two case–control studies found that the estrogen receptor-b
gene is associated with venous ulceration (Ashworth et al.,
2005, 2008).
Other studies on basic fibroblast growth factor (Seidman
et al., 2003) and interleukin-10 (Li et al., 1998) suggested
possible contribution of these molecules to the chronicity of
venous ulcers.
In addition, studies by Margolis et al. (2002) have
demonstrated the protective roles of estrogen and b-
adrenergic receptors on the development of venous ulcers.
A 2002 case–control study in the United Kingdom evaluated
women who received hormone replacement therapy and
found the relative risks of venous ulcer and pressure ulcer
development to be 0.65 (95% confidence interval 0.61–0.69)
and 0.68 (0.62–0.76) compared with those who did not use
hormone replacement therapy. For patients exposed to
b-adrenergic agonists, the odds ratio of association between
b-adrenergic receptor agonists and venous leg ulcer was
reported to be 0.84 (95% confidence interval, 0.82–0.86;
Margolis et al., 2007).
MMPs and tissue inhibitors of metalloproteinases (TIMPs)
MMPs, a family of zinc-dependent endoproteinases well-
known for their tissue remodeling properties, have also been
implicated in the pathogenesis of chronic venous disease,
given their well-established involvement in inflammation and
wound repair. In general, this family of enzymes is not
expressed in healthy, non-injured tissue; however, under
remodeling processes, such as inflammation and tissue
growth, its expression becomes highly regulated. For
example, MMP-1 has been shown to have an integral part
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in wound repair through cleavage of fibrillar type I collagen,
which then in turn initiates keratinocyte movement and
directionality during reepithelialization (Pilcher et al., 1997).
On the other hand, TIMPs, inhibitors of MMPs by binding
their catalytic sites, have also been extensively studied
because of their ability to prevent excessive breakdown of
extracellular matrix (Visse and Nagase, 2003). An intricate
balance between MMPs and TIMPs is thus necessary for
proper wound healing. Imbalance can lead to overactivation
of MMPs, resulting in uncontrolled proteolysis as seen
in chronic inflammatory states (Chakraborti et al., 2003).
Initially, higher levels of proteolytic activity were found in
patients with chronic venous ulcers than in those with acute
wounds (Palolahti et al., 1993). Elastase (Shields et al., 1994;
Grinnell and Zhu, 1996; Yager et al., 1997), gelatinase,
collagenase (Weckroth et al., 1996), and plasmin (Herouy
et al., 2000) were all found to be proteinease candidates;
thus, many later studies took a broader approach and
analyzed multiple MMPs. MMP-1 (Weckroth et al., 1996;
Herouy et al., 1998, 2000; Nwomeh et al., 1999; Beidler
et al., 2008; Subramaniam et al., 2008), MMP-2 (Wysocki
et al., 1993; Herouy et al., 1998, 2000; Norgauer et al., 2002;
Beidler et al., 2008), MMP-8 (Weckroth et al., 1996;
Nwomeh et al., 1999), and MMP-9 (Wysocki et al., 1993;
Tarlton et al., 1999; Norgauer et al., 2002) were found to be
associated with the dysfunctional healing state of chronic
venous disease. One study suggested that the increased
proteolytic activity could cause abnormal growth factor
degradation (Yager et al., 1997). Another study suggested
that the overactivity of MMPs in chronic ulcers impairs
angiogenesis in the ulcer bed, since MMP-containing chronic
wound fluid impairs in vitro angiogenesis, and the addition of
inhibitors of MMP-2/9 reverses this impairment (Ulrich et al.,
2005). Trengove et al. (1999) found that the overall levels of
MMPs decreased as ulcers began to heal.
In addition to MMPs, enhancers of MMPs have also been
studied. Norgauer et al. (2002) suggested that the elevated
expressions of membrane type 1 MMP and membrane type 2
MMP, both activators of MMP, and of extracellular MMP
inducer (EMMPRIN; CD147) may further contribute to the
proteolytic activity seen in chronic venous ulcers. Herouy
et al. (2000) found that the expression and activity of
urokinase-type plasminogen activator, a fibrin-independent
plasminogen activator, and its receptor urokinase-type
plasminogen activator receptor, which potentiates activity
of MMP-2, were also elevated in venous ulcers.
At the same time, several studies had difficulty establishing
a strong association between MMPs and venous ulcers. Harris
et al. (1995) found no statistically significant differences in
collagenase levels between healing and non-healing leg
ulcers. Later studies found no statistically significant differ-
ence in MMP-2 (Mirastschijski et al., 2002; Mwaura et al.,
2006) or MMP-9 (Mirastschijski et al., 2002) concentrations
between healing and non-healing ulcers (Mwaura et al.,
2006). Meyer et al. (2008) found that MMP activities were
elevated in healing and non-healing ulcers, and that total
MMP levels did not differ between the groups. Interestingly,
Cook et al. (2000) found that chronic wound fibroblasts
exhibited decreased levels of active MMP-2 compared with
patient-matched uninvolved dermal fibroblasts. Margolis
et al. (1996) found that patients with lipodermatosclerosis
had significantly higher plasminogen activator inhibitor-1
than control patients. Finally, Herrick et al. (1997) found
downregulation of elastases in chronic ulcer compared with
acute wounds.
Despite these conflicting data, several treatments were
devised to target the potentially excessive proteolytic
environment of venous ulcers. In a double-blinded, rando-
mized, controlled trial, pentoxifylline was shown to induce
an approximately 50% decrease in local elastase (Mirshahi
et al., 1995). Another randomized, controlled, non-blinded
trial showed that chronic venous ulcer patients treated with
oxidized regenerated cellulose/collagen matrix had de-
creased activities of elastase, plasmin, and gelatinase, but
not MMP-2, compared with controls; however, there was no
difference in healing between the two groups (Smeets et al.,
2008). Nano-oligosaccharide factor, a compound aiming to
promote wound closure through inhibition of MMP activity,
has also been evaluated. In a double-blinded, randomized,
controlled trial, nano-oligosaccharide factor along with
compression was found to be superior in achieving 40%
area reduction of venous ulcer compared with control with
an odds ratio of 2.4 (95% confidence interval: 1.1–5.3;
P¼0.026; Schmutz et al., 2008). Interestingly, doxycycline,
an antibiotic in the tetracycline family, was also studied
extensively as a potential treatment for chronic venous ulcer,
given its inhibitory property on MMPs (Smith et al., 1999).
The role of TIMPs in venous ulcer formation has also been
studied. In chronic venous disease, gene expression of
TIMP-1 (Herouy et al., 1998, 2000) and -2 (Herouy et al.,
2000) was found to be decreased compared with normal,
healthy controls (Herouy et al., 2000). Likewise, non-healing
ulcers possessed lower levels of TIMP-1 compared with
healing ulcers (Nwomeh et al., 1999). In vitro, dermal
fibroblasts treated with chronic venous ulcer fluid showed
reduced production of TIMP-1 compared with fibroblasts
treated with acute wound fluid (Subramaniam et al., 2008).
Conflicting results, however, have also been reported. In
varicose veins, TIMP-1 was found to be elevated and MMP-2
to be decreased (Badier-Commander et al., 2000). Mwaura
et al. (2006) found no difference in TIMP-2 levels between
healing and non-healing ulcers.
DISCUSSION
‘‘Fibrin cuff’’ theory
The ‘‘fibrin cuff’’ theory was one of the first that attempted to
explain the pathogenesis of venous ulcer formation, attribut-
ing the cause of tissue hypoxia caused by the formation of
fibrin cuffs. However, as later studies showed, the elevated
level of tissue hypoxia may be unique to the venous ulcer
microenvironment (Neumann et al., 1996; Joshi and Sloan,
2004). In addition, as Herrick et al. (1992) pointed out, the
fibrin cuff may actually be fibrosis instead of mere fibrin
deposition. These data suggest that other underlying disorders
must also contribute to the process of tissue hypoxia and
inflammation. Therefore, the fibrin cuff theory provides a
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foundation, but the theory by itself may not fully explain the
underlying mechanism of chronic venous disease.
Inflammatory cell ‘‘trap’’ theory
The inflammatory cell ‘‘trap’’ theory is one of the earliest
extensions of the fibrin cuff hypothesis. A critical draw-
back with this theory is the lack of a direct link between
inflammatory cells and progression of chronic venous
disease. Although correlation between inflammatory cell
deposition and chronic venous disease has been suggested
by many studies, none was able to clearly establish
a causative relationship between the two. In addition, as
Table 1 points out, almost all of the studies on inflammatory
cells are done with 30 patients or less. Duplex ultrasound, the
gold standard in diagnosing venous reflux, was used in only
half of the studies. Finally, of the 18 observational or
interventional studies, 15 did not exclude patients with
diabetes (Burnand et al., 1982a, b; Coleridge Smith et al.,
1988; Thomas et al., 1988; Cheatle et al., 1990; Trengove
et al., 1996; Weyl et al., 1996; Loots et al., 1998; Takase
et al., 1999; Danielsson et al., 2003) or infection (Burnand
et al., 1982a, b; Coleridge Smith et al., 1988; Thomas et al.,
1988; Layton et al., 1994; Trengove et al., 1996; Weyl et al.,
1996; Loots et al., 1998; Takase et al., 1999; Abd-El-Aleem
et al., 2005). Given the effects of diabetes and infection on
chronic inflammation, it is difficult to clearly identify the role
of inflammatory cells in chronic venous disease.
Of the various therapies that target the inflammatory
cell aspect of chronic venous disease, flavinoid is gaining
the most momentum, partially owing to the various clinical
trials for Daflon 500. However, Scallon and Bell-Syer (2007)
have pointed out numerous problems in the industry-
sponsored meta-analysis by Coleridge Smith. First, only
Daflon 500 was reviewed. Second, the analysis lacked the
usual transparency expected from a systematic review, such
as the processes of patient selection and details of the data
analysis.
Although the inflammatory cell trap theory offers an
interesting perspective on the initiation of venous ulcers, the
current data do not provide adequate evidence to strongly
support this hypothesis. Further studies should focus on
demonstrating the exact role of leukocytes in the formation of
venous ulcers. Moreover, diabetes and infection should be
part of the exclusion criteria for selecting future patients,
given the contributory roles of two characteristics on chronic
inflammation. Finally, the sample size should be larger.
Cytokines/growth factors
Several difficulties arise in studying growth factors and
cytokines in venous ulcers. The most important is the
selection of a proper animal model, as no animal model
can truly reflect the disease process seen in venous ulcers
(Lindblad, 2000). Thus, the next most appropriate step is to
directly study the patient population, which has several
Table 1. Observational and interventional studies of the association between inflammatory cells and chronic
venous disease
Reference, year
Number of
patients
Is diabetes
excluded?
Is infection
excluded?
Was duplex ultrasound
specified in diagnosis?
Abd-El-Aleem et al., 2005 15 Yes Yes No
Beckert et al., 2006 119 No Yes Yes
Burnand et al., 1982a, b 21 No No No
Cheatle et al., 1990 14 No No Yes
10 No No No
Coleridge Smith, 2005 723 No need No need No need
Danielsson et al., 2003 10 Yes No Yes
Layton et al., 1994 20 No Yes No
Loots et al., 1998 25 No No No
Pappas et al., 1995 11 Yes Yes Yes
Pappas et al., 1997 30 Yes Yes Yes
Peyton et al., 1998 14 No Yes Yes
Saharay et al., 1997 30 Yes Yes Yes
Saharay et al., 1998 30 Yes Yes Yes
Takase et al., 1999 21 Yes No No
Thomas et al., 1988 20 No No No
Trengove et al., 1996 8 No No No
Weyl et al., 1996 27 No No No
Wilkinson et al., 1993 23 No No Yes
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limitations of its own. Of the various methods, the most
commonly used are tissue biopsy and wound fluid collection.
Others have introduced techniques such as protein analysis
from tissue homogenates (Beidler et al., 2009) and reverse
transcription–PCR (Cowin et al., 2001) in an attempt to
facilitate quantification.
A significant drawback of biopsy is its invasiveness and
painfulness, making patient consent difficult to obtain. On
the other hand, wound fluid collection has its own problems.
The process itself usually involves aspiration of sample fluid
that accumulates underneath transparent adhesive dressing
(Barone et al., 1998; Nwomeh et al., 1999). However, given
the myriad of collection methods available, the comparability
of results from separate studies becomes questionable
(Drinkwater et al., 2002). Not only that, the sizes and types
of the wounds used for fluid collection are often not
standardized, increasing the variability among samples.
Drinkwater et al. (2002) noted that ‘‘chronic wounds’’ and
leg ulcers are often classified in a single group, despite their
possibly different etiologies, suggesting that a more homo-
genous population is required for proper study. Moreover,
wound fluid may not always be collected from patients,
simply because the patient’s ulcer was dry or had healed
before fluid could be collected Gohel et al., 2008). Because
of this problem, Gohel et al. (2008) pointed out that the
results from wound fluid assessment may be more represen-
tative of large venous ulcers than all venous ulcers.
There is also a great deal of variation in the levels of
growth factors and cytokines among individual patients,
making it difficult to determine whether a particular level is
normal or pathological. Although paired wound fluid and
blood samples can be drawn to provide better reference
points, the success rate of obtaining both samples is not
always high.
Table 2. Observational and interventional studies of the association between cytokine/growth factors and chronic
venous disease
Reference, year
Number of
patients
Is diabetes
excluded?
Is infection
excluded?
Was duplex ultrasound
specified in diagnosis?
Ambrosch et al., 2008 45 Yes No Yes
Ashworth et al., 2005 120 No No No
Ashworth et al., 2008 124 Yes No No
Beidler et al., 2009 30 No Yes Yes
Charles et al., 2009 5 No Yes No
Cowin et al., 2001 12 Yes No No
Cowin et al., 2006 16 Yes No No
Da Costa et al., 1999 60 Yes Yes No
Gohel et al., 2008 80 Yes No Yes
Harris et al., 1995 18 No Yes No
Hasan et al., 1997 7 No No No
HIgley et al., 1995 12 No No No
Kim et al., 2003 4 No Yes Yes
Lal et al., 2003 16 No Yes Yes
Li et al., 1998 20 No No No
Margolis et al., 2002 44,195 No No No
Margolis et al., 2007 414,887 No No No
Mendez et al., 1999 4 No Yes No
Murphy et al., 2002 8 Yes No Yes
Pappas et al., 2009 13 No No Yes
Raffetto et al., 2008 5 Yes Yes Yes
Robson et al., 2001 94 No No No
Seidman et al., 2003 7 Yes Yes Yes
Tian and Stacey, 2003 21 No No No
Trengove et al., 2000 26 No No No
Wallace and Stacey, 1998 21 Yes No No
Wallace et al., 2006 181 Yes No No
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Studies on wound fluid often attempt to analyze a large
number of cytokines and growth factors simultaneously
(Harris et al., 1995; Trengove et al., 2000; Tian and Stacey,
2003; Gohel et al., 2008; Beidler et al., 2009). Although
this design may be useful as an initial screening test
for identifying candidate cytokines and growth factors, it is
unsuitable for comparing individual cytokines and growth
factors from study to study. The general changes in various
cytokine levels detected in individual studies do not
necessarily imply that a specific cytokine (e.g., TNF-a) is
directly involved. The studies employ too general a variable
to allow any conclusions to be made about specific factors.
Compounding these limitations is the fact that almost all of
the samples include less than 30 patients (Harris et al., 1995;
Higley et al., 1995; Hasan et al., 1997; Li et al., 1998;
Wallace and Stacey, 1998; Mendez et al., 1999; Trengove
et al., 2000; Cowin et al., 2001, 2006; Murphy et al., 2002;
Kim et al., 2003; Lal et al., 2003; Seidman et al., 2003; Tian
and Stacey, 2003; Raffetto et al., 2008; Beidler et al., 2009;
Charles et al., 2009; Pappas et al., 2009). Chronic venous
disease patients are especially difficult to recruit into clinical
studies. Given the already small pool of available patients,
researchers often cannot construct the stringent exclusion
criteria necessary to control for confounding factors. Of the
20 studies involving wound fluid or ulcer biopsies, 17 did not
exclude patients with diabetes (Harris et al., 1995; Higley
et al., 1995; Hasan et al., 1997; Li et al., 1998; Mendez et al.,
1999; Trengove et al., 2000; Kim et al., 2003; Lal et al., 2003;
Tian and Stacey, 2003; Beidler et al., 2009; Charles et al.,
2009) or infection (Higley et al., 1995; Hasan et al., 1997;
Table 3. Observational and interventional studies of the association between MMP/TIMP and chronic venous
disease
Reference, year
Number of
patients
Is diabetes
excluded?
Is infection
excluded?
Was duplex ultrasound
specified in diagnosis?
Badier-Commander et al., 2000 12 No No No
Beidler et al., 2008 29 No No Yes
Cook et al., 2000 4 Yes Yes No
Grinnell and Zhu, 1996 3 No No No
Harris et al., 1995 18 No Yes No
Herouy et al., 1998 7 No No Yes
Herouy et al., 2000 19 No No Yes
Herouy et al., 2000 23 No No Yes
Herrick et al., 1997 5 Yes Yes No
Margolis et al., 1996 30 No No No
Meyer et al., 2008 27 No No Yes
Mirastschijski et al., 2002 34 No Yes No
Mirshahi et al., 1995 10 No No No
Mwaura et al., 2006 40 Yes No Yes
Norgauer et al., 2002 12 No No Yes
Nwomeh et al., 1999 13 Yes Yes No
Palolahti et al., 1993 17 No No No
Schmutz et al., 2008 117 No Yes No
Smeets et al., 2008 27 No No No
Subramaniam et al., 2008 9 Yes No No
Shields et al., 1994 45 Yes Yes Yes
Tarlton et al., 1999 25 No No No
Trengove et al., 1999 25 No Yes No
Ulrich et al., 2005 20 Yes Yes No
Weckroth et al., 1996 10 Yes No No
Wysocki et al., 1993 6 No No No
Yager et al., 1997 10 No Yes No
Zamboni et al., 2005 30 No No Yes
Abbreviations: MMP, matrix metalloproteinase; TIMP, tissue inhibitors of metalloproteinase.
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Li et al., 1998; Wallace and Stacey, 1998; Trengove et al.,
2000; Cowin et al., 2001, 2006; Murphy et al., 2002; Tian
and Stacey, 2003; Gohel et al., 2008). This weakness is
especially important in studies on TNF-a, given its known
positive association with the severity of active infection
(Ambrosch et al., 2008).
At this point, evidence linking cytokines with inflamma-
tion in chronic venous disease remains weak. There is no
clear indication that pro-inflammatory cytokines and growth
factors are increased in chronic venous ulcers or that TGF-b
and TNF-a are actively involved in the chronicity of the
disease. Future studies with larger sample sizes and more
complete exclusion criteria are needed to better address these
questions.
MMPs and TIMPs
Currently, the data surrounding MMPs and TIMPs remain
slightly conflicting, with the general trend showing over-
activity of MMPs and underactivity of TIMPs in non-healing
venous ulcers. Many of the problems present in the studies
of cytokine and growth factors are also present in the studies
for MMPs and TIMPs. Small sample size remains a problem,
with most sample sizes still below 30 patients (Palolahti
et al., 1993; Wysocki et al., 1993; Harris et al., 1995;
Mirshahi et al., 1995; Grinnell and Zhu, 1996; Weckroth
et al., 1996; Herrick et al., 1997; Yager et al., 1997; Herouy
et al., 1998, 2000; Nwomeh et al., 1999; Tarlton et al., 1999;
Trengove et al., 1999; Badier-Commander et al., 2000; Cook
et al., 2000; Norgauer et al., 2002; Ulrich et al., 2005;
Zamboni et al., 2005; Beidler et al., 2008; Meyer et al., 2008;
Smeets et al., 2008; Subramaniam et al., 2008). Great
variation of MMP concentrations from patient to patient
further complicates the issue. Failure to exclude patients with
diabetes or ulcer infection remains an issue. Overall, the role
of MMP/TIMP in venous ulcers remains unclear.
MATERIALS AND METHODS
We conducted a review of the relationship between inflammation
and chronic venous ulcers. ‘‘Inflammation,’’ ‘‘MMP,’’ ‘‘cytokine,’’
‘‘leukocyte,’’ and ‘‘varicose ulcer’’ were the main keywords used,
including all possible synonyms. Pubmed and bibliography reviews
were searched. Articles published in languages other than English
were reviewed if English translations were available. Observational
and interventional human studies with participants of any age, sex,
or health status were included. Articles whose main focus was not
the inflammatory mechanism, cytokines, leukocytes, and MMPs
were excluded. Clinical trials without controls, or nonrandomized
trials and case reports were also excluded. Final selection for articles
pertaining to inflammatory cells, cytokines/growth factors, and
MMPs are listed in Tables 1–3, respectively.
CONCLUSION
Current evidence does not strongly affirm the validity of the
fibrin cuff theory, inflammatory cell trap theory, cytokines/
growth factor sequestration theory, or the MMP/TIMP
imbalance theory. Difficulty in obtaining a sample size large
enough to provide conclusive result remains a universal
challenge for all studies. Duplex ultrasound, rather than
clinical diagnosis or Doppler ultrasound, should be used as
the primary method of diagnosing venous ulcers. To provide
a better understanding of the inflammatory etiology of
chronic venous ulcers, larger sample sizes with more
stringent inclusion and exclusion criteria are necessary.
Moreover, we propose that a national repository of wound
fluid and biopsy results be established, with an associated
patient information database. This would provide investi-
gators access to more detailed patient information, including
age, gender, duration of disease, and classification of disease
severity, to correlate with research findings gleaned from the
banked wound tissues and fluids. The creation of such a
repository database can provide researchers with much richer
data for future analysis and extrapolation of treatment
modalities.
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